Pharmaceutical giant Organon (NYSE: OGN) announced it will acquire Dermavant Sciences Ltd. from Roivant, in a private target merger valued at $1.2 billion.  Under the terms of the merger agreement, Organon will pay $175 million up front and a $75 million milestone payment upon regulatory approval, as well as...

Soon after emergency response teams scramble into action to address chemical fires, explosions, or other toxic events, attorneys begin gathering and analyzing information either to mitigate corporate risk or to seek remedies for anyone impacted by such an event. Listen...